Dr. Pecora on the CPIT001 Study in Hematologic Malignancies

Andrew L. Pecora, MD
Published: Friday, Dec 15, 2017



Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the CPIT001 study for patients with hematologic malignancies.

The CPIT001 trial is investigating the safety and efficacy of the combination of ipilimumab (Yervoy) and nivolumab (Opdivo) following autologous stem cell transplant in patients with high-risk hematologic malignancies. The first 29 patients enrolled experienced adverse events but those were not unexpected, says Percora.
 


Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the CPIT001 study for patients with hematologic malignancies.

The CPIT001 trial is investigating the safety and efficacy of the combination of ipilimumab (Yervoy) and nivolumab (Opdivo) following autologous stem cell transplant in patients with high-risk hematologic malignancies. The first 29 patients enrolled experienced adverse events but those were not unexpected, says Percora.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Overcoming Chronic Iron Overload in Pediatric AML and MDSJun 30, 20181.0
Oncology Briefings™: Updates in Rare Hematology: Advancing Care and Improving Outcomes for Patients with Aplastic AnemiaAug 31, 20181.0
Publication Bottom Border
Border Publication
x